Improving the accuracy of exosome protein marker quantification for pancreatic cancer treatment
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers
This study is looking at a new way to better understand tiny particles called exosomes in your blood, which can help doctors see how well your treatment for advanced pancreatic cancer is working, so they can make smarter choices about your care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11011274 on NIH RePORTER |
What this research studies
This research focuses on enhancing the methods used to isolate and analyze exosomes, which are tiny particles released by cells that can provide important information about cancer treatment responses. By developing a new technique called super-SILAC, the researchers aim to create a universal internal standard that will improve the reproducibility and accuracy of exosomal protein measurements in patients with advanced pancreatic cancer. This could lead to better monitoring of treatment effectiveness and more informed decisions regarding therapy adjustments. Patients' serum samples will be analyzed to identify novel biomarkers that indicate how well their treatment is working.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with locally advanced pancreatic cancer undergoing chemotherapy and radiation therapy.
Not a fit: Patients with early-stage pancreatic cancer or those not receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of treatment responses in pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using exosomal protein markers for cancer treatment monitoring, but this specific approach is novel and aims to address reproducibility issues.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lubman, David M. — University of Michigan at Ann Arbor
- Study coordinator: Lubman, David M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.